Pain management programme leads to radical reduction in opioid prescriptions

A new pain management programme implemented by surgeons in large healthcare systems led to a 64% reduction in opioid prescriptions of five or more days.

Although the role of prescriptions is widely documented in the ongoing US opioid epidemic, it’s only recently been shown that prescriptions lasting longer than five days have been identified as a risk factor for longer-term opioid use.

As some surgeons’ prescribing patterns have been found to be part of the problem, the surgical community is now working hard to address it.

A recent solution has been enacted by a large healthcare system in central Texas, where surgeons implemented a pain management programme that reduced longer-term prescriptions by two-thirds, according to a study published in the Journal of the American College of Surgeons.

The programme reduced post-surgery opioid prescriptions at Baylor Scott & White (BSW) hospitals of more than five days by 64%, from 1,228 in the three months before the programme started to 432 in the first three months of 2019. Prescriptions of less than five days duration increased 15%, from 5,133 to 5,923.

“Opioid prescriptions of over five days have been shown to dramatically increase addiction to opioids,” said lead study author Richard Frazee, a general surgeon at BSW Healthcare in Temple, Texas. “We established a standard of opioid prescriptions of five days or less after elective surgery.”

The programme consisted of using the monthly surgical grand rounds – a conference of a hospital’s physicians, residents and medical students – to educate surgeons and anaesthesiologists about the opioid epidemic and how post-surgery opioid prescriptions contributed to it.

At these meetings, the rationale for limiting opioid prescriptions to five days or less was introduced. The program also used the electronic health record (EHR) to monitor each physician’s opioid prescribing practices and, after six months, tied this measure to the quality component of their compensation.

Overall, the study included 31,814 patients who had elective surgery at the hospitals from January 2018, when the program began, through March 2019. Over the five quarters the study observed, a greater proportion of opioid prescriptions shifted from more than five days to fewer than five days.

Changing the way surgeons prescribe pain medication after surgery was not easy, Dr. Frazee acknowledged. The researchers noted that surgeons’ prescribing patterns have been slow to respond nationally to the opioid crisis, citing a Kaiser Health News-Johns Hopkins analysis that found that surgeons frequently wrote prescriptions of 100 pills or more from 2011 to 2016.

“As always, to change surgeons’ behaviour you have to convince them that it is a benefit to their patients,” he said. “We had to overcome many years of misinformation on the ‘safety’ of liberal use of opioids after surgery.”

The programme is one that can easily be used in other hospitals and health systems, Dr. Frazee said.

“This is an issue that health-care providers and the public are increasingly aware of. The Baylor Scott & White Healthcare System has adopted and emphasised a culture of safety. This program offers a model for other health-care systems and individual surgeons to adopt in the care of their patients.”

But tackling opioid addiction requires a multipronged approach. “The opioid crisis is ongoing; this study is one step in the process to addressing it,” Dr. Frazee said. “A continued multipronged approach is needed that incorporates education, pharmaceutical reform, rehabilitation programs, and easy disposal of unneeded prescriptions.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...